Cited by 1,348Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Open access

Pauken, Kristen E., Sammons, Morgan A., Odorizzi, Pamela M., Manne, Sasikanth, Godec, Jernej, Khan, Omar, Drake, Adam M., Chen, Zeyu, Sen, Debattama R., Kurachi, Makoto, Barnitz, R. Anthony, Bartman, Caroline, Bengsch, Bertram, Huang, Alexander C., Schenkel, Jason M., Vahedi, Golnaz, Haining, W. Nicholas, Berger, Shelley L., Wherry, E. John·2016·Science

DOI 10.1126/science.aaf2807PMC PMC5484795

Open this paper in CoChat — free account

Abstract

epigenetic landscape. These data indicate that epigenetic fate inflexibility may limit current immunotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.aaf2807

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citation
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Self-citation
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
GenePattern 2.0
Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,053
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral Infections
Utzschneider, D. T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D. P., Calderon-Copete, S. P., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.021 · Cited by 1,105
Progenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral Infection
Paley, M., Kroy, D. C., Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett, B. E., Bikoff, E. K., Robertson, E. J., Lauer, G. M., Reiner, S. L., et al. (2012) · Science · doi:10.1126/science.1229620 · Cited by 903
Self-citation

Show all 37 references

Sorted by citations

Items 901–1,000 of 1,000

Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series
Ogawara, D., Soda, H., Tomono, H., Iwasaki, K., Hara, T., Jinnai, S., Funayama, T., Okuno, D., Taniguchi, H., Yoshida, M., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12844 · Cited by 8
c-Jun Overexpressing CAR-T Cells are Exhaustion-Resistant and Mediate Enhanced Antitumor ActivityPreprint
Lynn, R. C., Weber, E. W., Gennert, D. G., Sotillo, E., Xu, P., Good, Z., Anbunathan, H., Jones, R. C., Tieu, V., Granja, J. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/653725 · Cited by 8
Molecular Mechanisms Underpinning Immunometabolic Reprogramming: How the Wind Changes during Cancer Progression
Flati, I., Nolfi, M. D. V., Dall’Aglio, F., Vecchiotti, D., Verzella, D., Alesse, E., Capece, D., & Zazzeroni, F. (2023) · Genes · doi:10.3390/genes14101953 · Cited by 7
Restoring tumor antigenicity activates the “bystander” T cell immune cycle
Yang, Y., Yu, Q., Zhang, H., Liu, Y., Wang, H., Yang, N., Shi, Y., Zhang, W., Wu, Z., Huang, S., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.094 · Cited by 7
Epigenetic priming as a driver of memory recall and dysfunction in T cells
Metzemaekers, M., Rinzema, N. J., & Stadhouders, R. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241433 · Cited by 8
Unmasking immune checkpoint resistance in esophageal squamous cell carcinoma: Insights into the tumor microenvironment and biomarker landscape
Wang, Z., Zhang, R., Xu, Y., Yue, B., Zhang, J., & Wang, F. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i8.109489 · Cited by 7
Epigenetic control of tissue resident memory T cells
Lan, Z., Chen, Z., Yang, N., Liu, T., Li, S., Shi, Y., & Gu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1605972 · Cited by 8
Self-citation
CD7 regulates the persistence of terminally exhausted CD8+ T cells during chronic infection
Hyslop, S., Hofferek, C. J., Stegantseva, M. V., Kan, E., McCord, K. A., Alvarez, V. M., Xia, A. Y., Conarty, J. P., Wieland, A., & Hudson, W. H. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116316 · Cited by 8
Exploring the Tumor Microenvironment in Osteosarcoma: Driver of Resistance and Progression
Schmidt, A. A., Prasad, A., Huisman, A. R., Wakefield, M. R., & Fang, Y. (2025) · Cancers · doi:10.3390/cancers17193106 · Cited by 9
MARCO+ Tumor‐Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma
Chen, J., Mo, J., Wei, J., Qu, M., Dai, J., Kong, Y., Xu, H., Li, J., Yan, X., Cui, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202514600 · Cited by 7
Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy
Shi, X., Deng, W., Pan, Y., Chen, Y., Wang, Y., & Wu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691980 · Cited by 9
“However, even under PD-1/PD-L1 blockade, Tpex cells may fail to undergo the necessary epigenetic reprogramming required for effective differentiation into terminally exhausted CD8 + T cells (Tex-term), thereby contributing to immunotherapy resistance (42).”
Uridine depletion impairs CD8⁺ T cell antitumor activity through N-glycosylation
Xiao, J., Li, Z., Ding, Y., Zhu, K., Zheng, Z., Zhang, Y., Weng, J., Wang, F., Zhang, Y., Zeng, S., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.016 · Cited by 8
IL-7: a potential next-generation adjuvant for immune cell therapies
Hotchkiss, R. S., DiPersio, J. F., Yee, C., Pachynski, R. K., & van den Brink, M. R. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1736931 · Cited by 7
T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic malignancies: Mechanisms and implications
Muth, A., Holzem, A. M. E., Neumann, A.-S., Bücklein, V., Subklewe, M. S., & Philipp, N. (2026) · Med · doi:10.1016/j.medj.2026.101031 · Cited by 9
Mature Tertiary Lymphoid Structures in Breast Cancers Are Associated With Antitumor Immunity and Better Prognosis
Yu, S., Dekker, M., Zwager, M. C., Slagter‐Menkema, L., van der Sluis, T., Schroder, C. P., van Vugt, M. A. T. M., & van der Vegt, B. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101004 · Cited by 7
Overcoming melanoma resistance to immune checkpoint blockade therapy using nano-strategies
Ding, Y., Liu, C., Wu, Y., & Fu, F. (2023) · Biomedical Technology · doi:10.1016/j.bmt.2023.03.003 · Cited by 7
KLRG1-expressing CD8+ T cells are exhausted and polyfunctional in patients with chronic hepatitis B
Wang, L., Liao, F., Yang, L., Jiang, L., Duan, L., Wang, B., Mu, D., Chen, J., Huang, Y., Hu, Q., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303945 · Cited by 7
BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes
Arifin, M. Z., Leitner, J. M., Egan, D., Waidhofer‐Söllner, P., Kölch, W., Zhernovkov, V., & Steinberger, P. (2024) · iScience · doi:10.1016/j.isci.2024.110253 · Cited by 7
Memory vs memory‐like: The different facets of CD 8+ T‐cell memory in HCV infection
Hofmann, M., Wieland, D., Pircher, H., & Thimme, R. (2018) · Immunological Reviews · doi:10.1111/imr.12642 · Cited by 8
Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade
SahBandar, I. N., Chew, G. M., Corley, M. J., Pang, A. P. S., Tsai, N. C. S., Hanks, N., Khadka, V. S., Klatt, N. R., Hensley‐McBain, T., Somsouk, M., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002557 · Cited by 7
“Several factors have been reported to impact the efficacy of ICB in cancer, including the levels of HLA-DR expression on monocyte [6], impaired antigen processing and presentation [7], and the epigenetic stability of exhausted T cells [8].”
Background
Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
Ye, J., Ma, Y., Ou, Q., Yan, J., Ye, B., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.883367 · Cited by 7
Pan-Cancer Methylated Dysregulation of Long Non-coding RNAs Reveals Epigenetic Biomarkers
Zhao, N., Guo, M., Zhang, C., Wang, C., & Wang, K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.882698 · Cited by 7
“Methylated research in cancer patients has been shown to improve and maintain the efficiency of cancer treatment (Pauken et al., 2016; Sen et al., 2016; Marwitz et al., 2017).”
Background
Emerging Therapies in Penile Cancer
Alencar, A. M., & Sonpavde, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910335 · Cited by 7
“The Histone Deacetylases (HDAC) are a class of enzymes that play a crucial role of epigenetic modifications related to T cell differentiation and effector functions (48).”
Background
Transcriptome analysis of Homo sapiens and Mus musculus reveals mechanisms of CD8+ T cell exhaustion caused by different factors
Zhang, L., & Nishi, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274494 · Cited by 8
Efficacy of Bivalent CEACAM6/4-1BBL Genetic Vaccine Combined with Anti-PD1 Antibody in MC38 Tumor Model of Mice
Li, Y., Zhu, X., You, J., Zhang, B., Huang, X., & Jin, C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10775 · Cited by 7
Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
Leroyer, E. H., Ziegler, C., Moulin, C., Campidelli, A., Jacquet, C., Rubio, M., Feugier, P., & Pagliuca, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216574 · Cited by 7
Establishment of CD8+ T Cell Thymic Central Tolerance to Tissue-Restricted Antigen Requires PD-1
May, J. F., Kelly, R. G., Suen, A. Y. W., Kim, J. I., Kim, J., Anderson, C. C., Rayat, G. R., & Baldwin, T. A. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200775 · Cited by 6
Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in the Host’s Immunity
Mondelli, M. U., Ottolini, S., Oliviero, B., Mantovani, S., Cerino, A., Mele, D., & Varchetta, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010268 · Cited by 7
“In agreement with the above, other studies showed that checkpoint-blockade immunotherapy did not fundamentally reverse exhaustion-associated epigenetic changes, supporting the epigenetic irreversibility of exhausted T cells [106,107].”
Result
Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C
Peña‐Asensio, J., Sánchez, H. C., Torralba, M., Miquel, J., Sanz‐de‐Villalobos, E., & Larrubia, J. R. (2021) · Cells · doi:10.3390/cells10030538 · Cited by 8
“The exhaustion profile is fixed epigenetically and limits the duration of reinvigoration by PD-1 blockade [57,58], but we could perhaps surpass this effect by adding the immune-modulatory properties of the γc cytokines [30,59].”
Background
Interferons limit autoantigen-specific CD8+ T-cell expansion in the non-obese diabetic mouse
Jhala, G., Krishnamurthy, B., Brodnicki, T. C., Ge, T., Akazawa, S., Selck, C., Trivedi, P., Pappas, E. G., Mackin, L., Principe, N., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110747 · Cited by 7
Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy
Ito, Y., Inoue, S., & Kagoya, Y. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-024-00324-7 · Cited by 8
“The epigenetic profiles acquired by exhausted T cells were also maintained following the administration of anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies as immune checkpoint blockade therapy intended to reju-venate T cells and increase their survival and proliferation [45].”
Background
Immune cell triads reprogram exhausted CD8+ T cells for effective tumor elimination
Lise, V., Malenica, I., Roychoudhuri, R., & Lugli, E. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.010 · Cited by 6
Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
Peng, J., Zhai, X., Liu, X., Huang, Z., Wang, Y., Wu, P., Gao, R., & Meng, X. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102249 · Cited by 6
“Even with IBP, exhausted T-cells may not regain their full anti-tumor activity, hampering the desired response [24].”
Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review)
Lyu, X., Han, J., Chen, L., Zhou, Y., & Wang, W. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5762 · Cited by 6
PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion
Pauken, K. E., Markson, S. C., Conway, T. S., Juneja, V. R., Shahid, O., Burke, K. P., Rowe, J. H., Nguyen, T. H., Collier, J. L., Walsh, J. M. L., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20230542 · Cited by 6
Self-citation
Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications
Zhang, Y., Xu, Y., Wu, Q., Fu, X., Li, Y., & Li, A. (2025) · Theranostics · doi:10.7150/thno.116951 · Cited by 7
“Additionally, T-cell expansion and the abnormal elevation of inflammatory factors can lead to immune resistance or hypersensitivity reactions, further complicating therapeutic outcomes [14-16].”
Modeling Combination Therapies and T Cell Exhaustion Dynamics in the Tumor Under Immune Checkpoint Blockade
Lai, X., & Yu, T. (2025) · Bulletin of Mathematical Biology · doi:10.1007/s11538-025-01507-0 · Cited by 6
“Studies reveal that anti-PD-1/PD-L1 restores the function and survival of CD8 + T ex by functionally reinvigorating pre-existing PD-1 + CD8 + T ex populations rather than through de novo priming of PD-1 − naive CD8 + T cells (Pauken et al. 2016; Im et al. 2016; Kurtulus et al. 2019).”
Influential
Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
Sun, Y., Yang, H., Xu, Q., Li, X., Lou, J., Duan, J., Xu, J., Liu, Z., Xia, Y., Lin, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202508754 · Cited by 7
Obesity as a Whole-Body Regulatory Disorder: A Systems Biology Framework for Metaflammation, Accelerated Aging, and Colorectal Cancer Risk
Dutta, G., Mishra, P., Mishra, S. P., & Badhai, J. (2026) · Onco · doi:10.3390/onco6030031 · Cited by 7
“In parallel, persistent inflammatory and antigenic stimulation may promote checkpoint signaling and partial functional anergy, thereby limiting effective recognition and elimination of damaged or transformed epithelial cells [96].”
Emerging immunotherapies in the Hodgkin lymphoma armamentarium
Spinner, M. A., & Advani, R. H. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2349083 · Cited by 6
“The hypomethy-lating agents (HMAs), azacitidine, and decitabine, increase tumor immunogenicity, T-cell infiltration, and may synergize with PD-1 inhibitors to restore immunosurveillance [66,67].”
PVRIG is Expressed on Stem-Like T Cells in Dendritic Cell–Rich Niches in Tumors and Its Blockade May Induce Immune Infiltration in Non-Inflamed Tumors
Alteber, Z., Cojocaru, G., Granit, R. Z., Barbiro, I., Wool, A., Frenkel, M., Novik, A., Shuchami, A., Liang, Y., Carmi, V. D., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0752 · Cited by 6
Interconnected lineage trajectories link conventional and natural killer (NK)-like exhausted CD8+ T cells beneficial in type 1 diabetes
Witkop, E. M., Diggins, K. E., WIEDEMAN, A. E., Serti, E., Nepom, G. T., Gersuk, V. H., Fuchs, B., Long, S. A., & Linsley, P. S. (2024) · Communications Biology · doi:10.1038/s42003-024-06456-3 · Cited by 5
“In cancer patients, epigenetic stability limits the durability of Tex reinvigora-tionbyPD-1blockade 7,42 .”
Background
Type I Interferon Activates PD-1 Expression through Activation of the STAT1-IRF2 Pathway in Myeloid Cells
Liang, L., Yang, Y., Deng, K., Wu, Y., Li, Y., Bai, L., Wang, Y., & Lu, C. (2024) · Cells · doi:10.3390/cells13131163 · Cited by 6
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
Vredevoogd, D. W., Apriamashvili, G., Levy, P. L., Sinha, S., Huinen, Z. R., Visser, N. L., de Bruijn, B., Boshuizen, J., Veen, S. E. V. H.-V., Ligtenberg, M. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010145 · Cited by 6
Macrophage-derived Fgl2 dampens antitumor immunity through regulation of FcγRIIB+CD8+ T cells in melanoma
Bennion, K. B., Bazzano, J. M. R., Liu, D., Wagener, M. E., Paulos, C. M., & Ford, M. L. (2025) · JCI Insight · doi:10.1172/jci.insight.182563 · Cited by 6
“In addition to chronic antigen exposure and hypoxia at the tumor, receptor-ligand interactions between myeloid cells and CD8 + T cells can promote an environment where impaired T cell function, termed T cell exhaustion (6–9), limits patient immunother-apeutic response (10–12).”
Immune signatures predicting responses to immunomodulatory antibody therapy
Pawelec, G. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.003 · Cited by 6
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Salkeni, M. A., Shin, J. Y., & Gulley, J. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_2 · Cited by 6
Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation
Zang, C., Zhao, Y., Liu, G., Li, K., Qin, L., Zhang, Y., Sun, J., Wang, Q., Ma, L., Zhao, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982578 · Cited by 6
T‐cell exhaustion: A potential target biomarker of the tumour microenvironment affecting oesophageal adenocarcinoma
Peng, S., Han, X., Geng, W., & Zhao, L. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3496 · Cited by 7
“This suggests that the interaction between the TEX pathway and immune infiltration and immune cells may be a potential target to facilitate the development of novel tumour therapies for EAC.”
Influential
Current methods for the detection of glypican-3
Xiao, X., Huang, Q., Lin, X., Zahid, K. R., Huang, X., Liu, T., & Zeng, T. (2023) · Analytical Methods · doi:10.1039/d3ay01523h · Cited by 6
Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non–Small Cell Lung Cancer
Tseng, D., Padda, S. K., & Wakelee, H. A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.008 · Cited by 6
Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?
Pourmir, I., Gazeau, B., Basile, H. D. S., & Fabre, E. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.14 · Cited by 5
“Exhausted T-cells demonstrate altered anti-tumor function and decreased re-invigoration potential under ICI, as well as an impaired capacity to generate T memory cells([7,67,68]).”
Background
Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors
Sinha, D., Smith, C., & Khanna, R. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.005 · Cited by 6
CD226 Throttles up CD8+ T Cell Antitumor Activity
Philip, M. (2020) · Immunity · doi:10.1016/j.immuni.2020.09.013 · Cited by 6
Epigenetic Regulation in Breast Cancer
Nam, H. J., & Baek, S. H. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_5 · Cited by 7
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
Cooke, R. E., Koldej, R. M., & Ritchie, D. (2019) · Journal of Oncology · doi:10.1155/2019/2186494 · Cited by 5
Hepatitis C Virus as a Unique Human Model Disease to Define Differences in the Transcriptional Landscape of T Cells in Acute versus Chronic Infection
Wolski, D., & Lauer, G. M. (2019) · Viruses · doi:10.3390/v11080683 · Cited by 6
A Regenerative Perspective on Successful and Failed T-Cell ImmunityPreprint
Reiner, S. L. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a037937 · Cited by 6
Altered costimulatory signals and hypoxia support chromatin landscapes limiting the functional potential of exhausted T cells in cancerPreprint
Ford, B. R., Rittenhouse, N., Scharping, N. E., Vignali, P., Frisch, A. T., Peralta, R. M., Delgoffe, G. M., & Poholek, A. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.11.451947 · Cited by 6
Longitudinal single cell transcriptional and epigenetic mapping of effector, memory, and exhausted CD8 T cells reveals shared biological circuits across distinct cell fatesPreprint
Giles, J. R., Ngiow, S. F., Manne, S., Baxter, A. E., Khan, O., Wang, P., Staupe, R. P., Abdel-Hakeem, M. S., Huang, H., Mathew, D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.27.485974 · Cited by 6
“Furthermore, some subsets of TEFF and TMEM versus TEX have overlapping protein expression patterns, such as the “progenitor-associated” TF, TCF1.”
BackgroundInfluentialSelf-citation
TOX, through a glass, darkly
Hogan, P. G., Reveles, B. V., & Arteaga-Vazquez, L. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1576468 · Cited by 6
Downregulated Aryl Hydrocarbon Receptor Expression Is Linked with Increased IFN-γ Production and Impaired Immune Checkpoint Upregulation in Vitiligo
Belpaire, A., Demeyer, A., Berrevoet, D., Nieuwerburgh, F. V., Caelenberg, E. V., Papageorgiou, T., van Geel, N., & Speeckaert, R. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.07.027 · Cited by 5
Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity
Hoyt-Miggelbrink, A. M., Polania, J. W., Wachsmuth, L. P., Lorrey, S., Mohan, A. A., Hardigan, A. A., Blandford, E. E., Lerner, E., Wilkinson, D. S., Hotchkiss, K. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3455 · Cited by 6
“Finally, as the epigenetic stability of exhausted CD8 + T cells has been described as a key contributor to diminished long-term efficacy with PD-1 blockade (17), TNFR2 antagonism might provide a novel strategy to increase the success of ICIs.”
Association between Metabolic Reprogramming and Immune Regulation in Digestive Tract Tumors
Liu, J., Wang, T., Zhang, W., Huang, Y., Wang, X., & Li, Q. (2024) · Oncology Research and Treatment · doi:10.1159/000538659 · Cited by 5
Expanding the diagnostic toolbox for complex genetic immune disorders
Abrams, E. D., Basu, A., Thomas, M. E. Z., Henrickson, S. E., & Abraham, R. S. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.11.022 · Cited by 5
Challenges and opportunities of CAR T-cell therapies for CLL
Zhao, Z., Grégoire, C., de Oliveira, B. C., Chung, K., & Melenhorst, J. J. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.01.002 · Cited by 5
Lrp10 suppresses IL7R limiting CD8 T cell homeostatic expansion and anti-tumor immunity
Russell, J., Chen, L., Liu, A., Wang, J., Ghosh, S., Zhong, X. Y., Shi, H., Beutler, B., & Nair‐Gill, E. (2024) · EMBO Reports · doi:10.1038/s44319-024-00191-w · Cited by 5
“…of terminally exhausted cells IL7R expression on activated CD8 T cells marks cells with memory potential (Kaech et al, 2003) and is associated with enhanced responses to chronic viral infections and tumors (Belarif et al, 2018; Krishna et al, 2020; Micevic et al, 2023; Pauken et al, 2016).”
Understanding the HIV-specific T-cell response to immune checkpoint blockade: what can we learn from cancer immunotherapy?
Gubser, C., & Kaufmann, D. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000957 · Cited by 5
Epigenetic Remodeling in Exhausted T Cells
Laurie, S. J., & Ford, M. L. (2017) · Transplantation · doi:10.1097/tp.0000000000001720 · Cited by 5
Improved Functionality of Exhausted Intrahepatic CXCR5+ CD8+ T Cells Contributes to Chronic Antigen Clearance Upon Immunomodulation
Kumashie, K. G., Cebula, M., Hagedorn, C., Kreppel, F., Pils, M. C., Koch‐Nolte, F., Rissiek, B., & Wirth, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592328 · Cited by 5
Epigenetic networks driving T cell identity and plasticity during immunosenescence
Rodríguez, R. M. A., Sáiz, M. L., Suárez-Álvarez, B., & López‐Larrea, C. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.08.014 · Cited by 5
Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
Liu, S., Geng, S., Shi, N., Zhang, L., Xue, W., Li, Y. H., & Jiang, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878540 · Cited by 5
“In melanoma, TMB and neoantigen load predict patients’ response to CTLA-4 treatment (Pauken et al., 2016).”
Background
Dissecting the heterogeneity of exhausted T cells at the molecular level
Kagoya, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac016 · Cited by 5
A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy
Sun, Y. L., Han, R., Wang, J., Qin, Y., Ren, Z., Feng, X., Liu, Q., & Wang, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.057 · Cited by 5
Regulation of effector and memory CD8 + T cell differentiation: a focus on orphan nuclear receptor NR4A family, transcription factor, and metabolism
Oladipo, O. O., Adedeji, B. O., Adedokun, S. P., Gbadamosi, J. A., & Salaudeen, M. (2022) · Immunologic Research · doi:10.1007/s12026-022-09353-1 · Cited by 5
Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner
Muramatsu, T., Noguchi, T., Sugiyama, D., Kanada, Y., Fujimaki, K., Ito, S., Gotoh, M., & Nishikawa, H. (2020) · International Immunology · doi:10.1093/intimm/dxaa049 · Cited by 5
Endogenous HLA-DQ8αβ programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival
Knopick, P. L., Terman, D. S., Riha, N., Alvine, T., Larson, R., Badiou, C., Lina, G., Ballantyne, J. A., & Bradley, D. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001493 · Cited by 6
CAR T cells need a pitstop to win the race
Zebley, C. C., & Youngblood, B. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.011 · Cited by 5
Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma
Huppert, L. A., & DAUD, A. I. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00943 · Cited by 5
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control
Román, C. R. D., Erwin, M. M., Rudloff, M. W., Revetta, F. L., Murray, K. A., Favret, N. R., Roetman, J. J., Roland, J. T., Washington, M. K., & Philip, M. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009129 · Cited by 4
Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update
Lu, J., Yu, J., Xu, T., Li, Y., Chen, S., Zhou, Q., & Wang, L. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.126 · Cited by 5
Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer
Ito, K., Iida, K., Hirano, T., Leong, M. M., Morii, K., Menju, T., Date, H., Ozasa, H., Yoshida, H., Hirai, T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69680-x · Cited by 4
Acquired resistance of cancer therapies: Mechanisms and perspectives
Wang, M., Zhai, X., Li, J., Chen, J., Gai, X., Liu, X., Liu, Y., Zhou, Q., & Chen, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004048 · Cited by 5
“[87] Therefore, T cell exhaustion is not only a core in tumour immune escape but also a major obstacle to achieving long-term efficacy with current immunotherapies.”
DGAT1 mediates sex-specific CD8+ T cell antitumour responses
Madi, A., Shi, H., Su, M., Mady, A., Lv, B., Wang, H., Yang, B., Yan, Z., Jin, X., Wu, L., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01462-7 · Cited by 4
Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions
Kouro, T., Sasada, T., & Imai, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115010 · Cited by 5
Simulating CD8 T cell exhaustion: A comprehensive approach
Manrique-Rincón, A., Foster, B., Horswell, S. D., Goulding, D., Adams, D. J., & Speak, A. O. (2025) · iScience · doi:10.1016/j.isci.2025.112897 · Cited by 5
“Interestingly, HOXA2 was previously shown to be enriched in exhausted T cells from the LCMV model 43 .”
Background
Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions
Li, X., Wu, M., Lu, J., Yu, J., & Chen, D. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189084 · Cited by 4
T Cell Exhaustion in Allergic Diseases and Allergen Immunotherapy: A Novel Biomarker?
Xu, Q., Li, L., & Zhu, R. (2025) · Current Allergy and Asthma Reports · doi:10.1007/s11882-025-01199-5 · Cited by 7
“Notably, exhausted T cells exhibit stable epigenetic profiles minimally affected by checkpoint blockade [34, 35], although recent research by Kissick H et al. [36] suggests that Arid1a was associated with epigenetic modification, and eliminating Arid1a could restore proliferative and cytotoxic…”
Prevention of CAR-T-cell dysfunction
LaFleur, M. W., Miller, B. C., & Sharpe, A. H. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0512-2 · Cited by 4
A Review of Proteomics Strategies to Study T-Cell Activation and Function in Cancer Disease
Papale, M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1507-2_9 · Cited by 4
Nanotechnology and Immunomodulators in Cancer
Volovat, C. D., Volovăț, S. R., & Agop, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-6379-6_5 · Cited by 4
A binary module for microbiota-mediated regulation of γδ17 cells, hallmarked by microbiota-driven expression of programmed cell death protein 1
Huang, H.-I., Xue, Y., Jewell, M. L., Tan, C. Y., Theriot, B. S., Aggarwal, N., Dockterman, J., Lin, Y., Schroeder, E. A., Wang, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112951 · Cited by 4
“32,33,49 PD-1 expressed by follicular T helper cells is also permanent and critical for their function in germinal centers.”
Immunoediting is not a primary transformation event in a murine model of MLL-ENL AML
Dudenhöffer‐Pfeifer, M., & Bryder, D. (2018) · Life Science Alliance · doi:10.26508/lsa.201800079 · Cited by 3
“This reflected mainly an expansion of leukemic cells (Fig S2) but coincided also with an increase in CD8+ effector cells (Fig 2C), of which many expressed PD-1, an indicator of CD8+ T cell exhaustion (Pauken et al, 2016).”
A unique epigenomic landscape defines CD8 + tissue-resident memory T cellsPreprint
Buquicchio, F. A., Fonseca, R., Belk, J. A., Evrard, M., Obers, A., Qi, Y., Dániel, B., Yost, K. E., Satpathy, A. T., & Mackay, L. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.04.490680 · Cited by 4
UFL1 promotes survival and function of virtual memory CD8 T cells
Bhatt, B., Kumar, K., Shi, H., Ganesan, D., Anazodo, F. I., Rathakrishnan, A., Zhu, H., Wanna, A., Jiang, C., Jayavelu, T., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkae042 · Cited by 3
Anlotinib promotes CD4 + T cell infiltration and enhances the anti-tumor effect of PD-1 blockade in lung cancer
Zhang, M., Liu, L., Zheng, H., Chen, M., & Li, J. (2025) · Immunologic Research · doi:10.1007/s12026-025-09621-w · Cited by 4
The Role and Research Progress of CD8+ T Cells in Sepsis
Wang, X., Huang, Q. Y., Zuo, Z., Wang, Z., Zhang, L., & Qian, Z. (2025) · Biomedicines · doi:10.3390/biomedicines13122912 · Cited by 3
“…particular shapes the exhausted CD8 + T cell program by methylating promoters and regulatory regions of effector and memory-associated genes such as transcription factor 7 (Tcf7), while demethylation at loci encoding inhibitory receptors (e.g., PD-1) stabilizes their high-level expression [64–69].”
Comprehensive multi-omics analysis of CD36 in pan-cancers: Evaluating role in prognosis, immune microenvironment, and therapeutic response
Ashaq, M. S., Wang, S., Guo, M., Wang, L., Li, Z., Wang, Y., Huang, Y., Li, Y., & Zhao, B. (2025) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2025.100097 · Cited by 3
“…on survival and bulk transcriptomic data and require mechanistic evaluation, they still suggest a dual role of CD36, which is consistent with emerging evidence that progenitor-like exhausted T cells (TCF1 + PD-1 + ) can sustain ICB responsiveness in otherwise dysfunctional T-cell contexts [48].”
Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity
Zhang, X., Aimaiti, G., Guan, Y., Sha, Y., Zhou, W., Shen, J., Zhao, B., & Yuan, W. (2026) · Advanced Science · doi:10.1002/advs.202518547 · Cited by 3
“[ 137 ] More detailed applications of orthogonal IL-2/IL-2R systems are discussed in “ 4.”
T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy
Nouri, K., Aasadollahei, N., Haghir-Sharif-Zamini, Y., Seydi, H., Salehi, M., Mesdaghi, M., Najimi, M., & Vosough, M. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71044 · Cited by 5
“Among 6000 unique open chromatin regions (OCRs) distinguishing T EX from T EFF or T MEM state, only 650 OCRs were altered by PD-1 blockade, reflecting the stability of exhaustion-associated epigenetic programs [27, 40, 41].”

Authors: Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., Barnitz, R. A., Bartman, C., Bengsch, B., Huang, A. C., Schenkel, J. M., Vahedi, G., Haining, W. N., Berger, S. L., & Wherry, E. J.
Affiliations: University of Pennsylvania (US)
Harvard University (US)
Dana-Farber Cancer Institute (US)
University of Minnesota (US)
Broad Institute (US)
Corresponding author: Wherry, E. John
ORCID: Pauken, Kristen E.
Sammons, Morgan A.
Odorizzi, Pamela M.
Manne, Sasikanth
Godec, Jernej
Khan, Omar
Chen, Zeyu
Sen, Debattama R.
Kurachi, Makoto
Bartman, Caroline
Bengsch, Bertram
Huang, Alexander C.
Schenkel, Jason M.
Vahedi, Golnaz
Haining, W. Nicholas
Berger, Shelley L.
Wherry, E. John
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2016-12-02
Volume: 354
Issue: 6316
Pages: 1160-1165
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.aaf2807
PMC: PMC5484795
OpenAlex: W2541574334
Cited by: 1,348
References: 37
Citations by year: 2026: 162 · 2025: 128 · 2024: 122 · 2023: 160 · 2022: 145 · 2021: 166 · 2020: 162 · 2019: 129 · 2018: 106 · 2017: 66 · 2016: 2
FWCI: 54.40
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Robertson Foundation–Cancer Research Institute Irvington Fellowship
American Cancer Society Postdoctoral Fellowship
German Research Foundation Fellowship (BE5496/1-1)
National Institutes of Health (F30DK100159, T32 2T32CA009615-26, CA78831, AI105343, AI112521, AI082630, AI115712, AI117950, AI108545)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: exhausted T cells, epigenetic stability, anti-PD-1 therapy, T cell reinvigoration, T cell exhaustion
MeSH terms: Animals, Female, Immunologic Memory, Immunotherapy, Mice, Inbred C57BL, Transcription, Genetic, Interleukin-7, CD8-Positive T-Lymphocytes, Cell Lineage, Epigenesis, Genetic, Mice, Gene Regulatory Networks, B7-H1 Antigen, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks